NCT02023996 2024-12-10PET Imaging With 89Zr-DFO-Trastuzumab in Esophagogastric CancerMemorial Sloan Kettering Cancer CenterPhase NA Completed42 enrolled 11 charts
NCT02286843 2021-06-18Can HER2 Targeted PET/CT Imaging Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy?Memorial Sloan Kettering Cancer CenterPhase NA Completed49 enrolled 8 charts
NCT01832051 2015-11-05Clinical Value of 89Zr-trastuzumab PETUniversity Medical Center GroningenPhase 2 Completed20 enrolled